Bellicum Pharmaceuticals


Tricida, Inc., is a privately-held, late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally dosed polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).

Select Venture Capital & Financial Partners

OrbiMed Advisors Venrock Wellington Management